首页 > 最新文献

Journal of Medicine, Surgery, and Public Health最新文献

英文 中文
Sociodemographic differences in skilled nursing facility discharge among Parkinson’s disease related healthcare utilizers 帕金森氏病相关医疗保健使用者中熟练护理机构出院的社会人口统计学差异
Pub Date : 2026-01-20 DOI: 10.1016/j.glmedi.2026.100226
Jalal Uddin , Nicole V. DeVille , Miguel Fudolig , Chad L. Cross , Merrill R. Landers , Jason D. Flatt

Background

Parkinson’s disease (PD) is a progressive neurodegenerative disorder that often results in increased healthcare utilization and long-term care needs. While national trends have highlighted differences in institutional care utilization, limited research has examined factors associated with discharge to skilled nursing facilities (SNF) among PD healthcare utilizers in Nevada.

Methods

We conducted a retrospective analysis of PD-related healthcare utilization records from the Nevada Center for Health Information Analysis (CHIA) between 2013 and 2021 (N = 64,088). Parkinson’s disease and parkinsonism were identified using ICD-9 and ICD-10 codes in any diagnosis position. The primary outcome was discharge to an SNF. Bivariate analyses and multivariable logistic regression models were used to examine associations between SNF discharge and demographic, temporal, geographic, and utilization-related factors. Adjusted odds ratios (aORs) and 95 % confidence intervals (CIs) were estimated.

Results

Overall, 13.2 % of PD-related healthcare encounters resulted in discharge to an SNF. In adjusted analyses, older age was associated with higher odds of SNF discharge (aOR = 1.027 per year; 95 % CI: 1.025–1.030; p < 0.001). Inpatient admissions were strongly associated with SNF discharge compared with outpatient encounters (aOR = 5.934; 95 % CI: 5.493–6.410; p < 0.001). Compared with White healthcare utilizers, Black (aOR = 1.599; 95 % CI: 1.457–1.756; p < 0.001) and Native American or Alaskan Native individuals (aOR = 2.389; 95 % CI: 1.864–3.062; p < 0.001) had significantly higher odds of SNF discharge. Residents of rural (aOR = 0.477; 95 % CI: 0.424–0.536) and frontier areas (aOR = 0.547; 95 % CI: 0.491–0.608) were less likely to be discharged to an SNF compared with urban residents (both p < 0.001).

Conclusion

This study highlights demographic differences in discharge to an SNF among PD healthcare utilizers in Nevada. Findings underscore the need to address differences in long-term care access options and promote alternative discharge settings especially among racial and ethnic minority communities. Ensuring access to personalized care options could help to improve quality of life and provide support for people with PD.
帕金森病(PD)是一种进行性神经退行性疾病,经常导致医疗保健利用率和长期护理需求的增加。虽然国家趋势突出了机构护理利用的差异,但有限的研究已经检查了内华达州PD医疗保健使用者中与熟练护理设施(SNF)出院相关的因素。方法回顾性分析2013 - 2021年内华达州卫生信息分析中心(CHIA) pd相关医疗保健利用记录(N = 64,088)。在任何诊断位置使用ICD-9和ICD-10代码来识别帕金森病和帕金森症。主要结局是进入SNF。采用双变量分析和多变量logistic回归模型来检验SNF排放与人口、时间、地理和利用相关因素之间的关系。估计校正优势比(aORs)和95% %置信区间(ci)。结果总体而言,13.2 %的pd相关医疗保健遭遇导致出院到SNF。在调整分析中,年龄越大SNF出院的几率越高(aOR = 1.027 /年;95 % CI: 1.025-1.030; p <; 0.001)。与门诊患者相比,住院患者入院与SNF出院密切相关(aOR = 5.934; 95 % CI: 5.493-6.410; p <; 0.001)。与白人医疗保健使用者相比,黑人(aOR = 1.599; 95 % CI: 1.457-1.756; p <; 0.001)和美洲原住民或阿拉斯加原住民(aOR = 2.389; 95 % CI: 1.864-3.062; p <; 0.001)SNF出院的几率显著高于白人。与城市居民相比,农村居民(aOR = 0.477; 95 % CI: 0.424-0.536)和边疆地区居民(aOR = 0.547; 95 % CI: 0.491-0.608)更不可能被送往SNF (p均为 <; 0.001)。结论:本研究强调了内华达州PD医疗保健使用者在SNF出院方面的人口统计学差异。研究结果强调需要解决长期护理选择的差异,并促进替代出院环境,特别是在种族和少数民族社区。确保获得个性化的护理选择可以帮助改善生活质量,并为PD患者提供支持。
{"title":"Sociodemographic differences in skilled nursing facility discharge among Parkinson’s disease related healthcare utilizers","authors":"Jalal Uddin ,&nbsp;Nicole V. DeVille ,&nbsp;Miguel Fudolig ,&nbsp;Chad L. Cross ,&nbsp;Merrill R. Landers ,&nbsp;Jason D. Flatt","doi":"10.1016/j.glmedi.2026.100226","DOIUrl":"10.1016/j.glmedi.2026.100226","url":null,"abstract":"<div><h3>Background</h3><div>Parkinson’s disease (PD) is a progressive neurodegenerative disorder that often results in increased healthcare utilization and long-term care needs. While national trends have highlighted differences in institutional care utilization, limited research has examined factors associated with discharge to skilled nursing facilities (SNF) among PD healthcare utilizers in Nevada.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of PD-related healthcare utilization records from the Nevada Center for Health Information Analysis (CHIA) between 2013 and 2021 (N = 64,088). Parkinson’s disease and parkinsonism were identified using ICD-9 and ICD-10 codes in any diagnosis position. The primary outcome was discharge to an SNF. Bivariate analyses and multivariable logistic regression models were used to examine associations between SNF discharge and demographic, temporal, geographic, and utilization-related factors. Adjusted odds ratios (aORs) and 95 % confidence intervals (CIs) were estimated.</div></div><div><h3>Results</h3><div>Overall, 13.2 % of PD-related healthcare encounters resulted in discharge to an SNF. In adjusted analyses, older age was associated with higher odds of SNF discharge (aOR = 1.027 per year; 95 % CI: 1.025–1.030; p &lt; 0.001). Inpatient admissions were strongly associated with SNF discharge compared with outpatient encounters (aOR = 5.934; 95 % CI: 5.493–6.410; p &lt; 0.001). Compared with White healthcare utilizers, Black (aOR = 1.599; 95 % CI: 1.457–1.756; p &lt; 0.001) and Native American or Alaskan Native individuals (aOR = 2.389; 95 % CI: 1.864–3.062; p &lt; 0.001) had significantly higher odds of SNF discharge. Residents of rural (aOR = 0.477; 95 % CI: 0.424–0.536) and frontier areas (aOR = 0.547; 95 % CI: 0.491–0.608) were less likely to be discharged to an SNF compared with urban residents (both p &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>This study highlights demographic differences in discharge to an SNF among PD healthcare utilizers in Nevada. Findings underscore the need to address differences in long-term care access options and promote alternative discharge settings especially among racial and ethnic minority communities. Ensuring access to personalized care options could help to improve quality of life and provide support for people with PD.</div></div>","PeriodicalId":100804,"journal":{"name":"Journal of Medicine, Surgery, and Public Health","volume":"8 ","pages":"Article 100226"},"PeriodicalIF":0.0,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146037051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Condom use in Indonesia: Interplay with societal norms and human rights 印度尼西亚的安全套使用:与社会规范和人权的相互作用
Pub Date : 2026-01-02 DOI: 10.1016/j.glmedi.2026.100225
Aga Natalis
Indonesia faces significant challenges in advancing condom utilization initiatives due to the absence of explicit support from religious institutions. This has complicated HIV/AIDS prevention strategies, particularly adolescent contraceptives provision under Government Regulation No. 28 of 2024. The Indonesian Ulema Council’s opposition to these provisions, based on Islamic principles, contrasts with governmental health objectives aimed at reducing early marriage, infant mortality, and stunting. Despite the country’s commitment to fighting HIV, the epidemic remains critical, with sexual transmission accounting for the majority of new infections. Vulnerable groups – including adolescents, men who have sex with men, transgender individuals, and sex workers – are disproportionately affected by stigma, discrimination, and limited access to health services. This commentary argues that Indonesia’s regulatory framework subordinates’ constitutional health guarantees to moral enforcement, creating institutional barriers that compromise reproductive rights. It calls for legal reforms to decriminalise consensual extramarital relations, ensure universal condom distribution, and implement comprehensive sexuality education, alongside destigmatisation campaigns and mandatory training for healthcare providers to address implicit bias. By recognizing condoms as a human right and dismantling socio-legal barriers, Indonesia can create an inclusive, health-focused framework that empowers informed sexual health decisions. These reforms are essential for addressing the HIV epidemic and promoting reproductive autonomy in Indonesia.
由于缺乏宗教机构的明确支持,印度尼西亚在推进避孕套使用倡议方面面临重大挑战。这使得艾滋病毒/艾滋病预防战略复杂化,特别是根据2024年第28号政府条例提供的青少年避孕药具。印度尼西亚乌里玛理事会基于伊斯兰原则反对这些规定,这与政府旨在减少早婚、婴儿死亡率和发育迟缓的保健目标形成鲜明对比。尽管该国致力于防治艾滋病毒,但这一流行病仍然很严重,性传播占新感染病例的大多数。弱势群体——包括青少年、男男性行为者、跨性别者和性工作者——不成比例地受到污名化、歧视和获得卫生服务的机会有限的影响。这篇评论认为,印度尼西亚的监管框架将宪法健康保障置于道德执行之下,造成了损害生殖权利的制度障碍。它呼吁进行法律改革,使双方自愿的婚外关系合法化,确保普遍发放避孕套,实施全面的性教育,同时开展去污名化运动,并对医疗保健提供者进行强制性培训,以消除隐性偏见。通过承认避孕套是一项人权并消除社会法律障碍,印度尼西亚可以建立一个包容的、以健康为重点的框架,使人们能够在知情的情况下做出性健康决定。这些改革对于解决印度尼西亚的艾滋病毒流行病和促进生殖自主至关重要。
{"title":"Condom use in Indonesia: Interplay with societal norms and human rights","authors":"Aga Natalis","doi":"10.1016/j.glmedi.2026.100225","DOIUrl":"10.1016/j.glmedi.2026.100225","url":null,"abstract":"<div><div>Indonesia faces significant challenges in advancing condom utilization initiatives due to the absence of explicit support from religious institutions. This has complicated HIV/AIDS prevention strategies, particularly adolescent contraceptives provision under Government Regulation No. 28 of 2024. The Indonesian Ulema Council’s opposition to these provisions, based on Islamic principles, contrasts with governmental health objectives aimed at reducing early marriage, infant mortality, and stunting. Despite the country’s commitment to fighting HIV, the epidemic remains critical, with sexual transmission accounting for the majority of new infections. Vulnerable groups – including adolescents, men who have sex with men, transgender individuals, and sex workers – are disproportionately affected by stigma, discrimination, and limited access to health services. This commentary argues that Indonesia’s regulatory framework subordinates’ constitutional health guarantees to moral enforcement, creating institutional barriers that compromise reproductive rights. It calls for legal reforms to decriminalise consensual extramarital relations, ensure universal condom distribution, and implement comprehensive sexuality education, alongside destigmatisation campaigns and mandatory training for healthcare providers to address implicit bias. By recognizing condoms as a human right and dismantling socio-legal barriers, Indonesia can create an inclusive, health-focused framework that empowers informed sexual health decisions. These reforms are essential for addressing the HIV epidemic and promoting reproductive autonomy in Indonesia.</div></div>","PeriodicalId":100804,"journal":{"name":"Journal of Medicine, Surgery, and Public Health","volume":"8 ","pages":"Article 100225"},"PeriodicalIF":0.0,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145938935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral health disparities between LGB and non-LGB individuals in the United States 美国LGB和非LGB人群的口腔健康差异
Pub Date : 2025-12-23 DOI: 10.1016/j.glmedi.2025.100223
R. Andrew Yockey
This study examines potential oral health disparities among both heterosexual and sexual minority adults while also investigating sex-based differences in the association between sexual orientation and poor oral health. Pooled data (2007–2016) were used from the National Health and Nutrition Examination Survey for men and women aged 18–59. Multiple logistic regression models were used to examine the association between sexual orientation and self-reported oral health. Data from 20,298 participants were included in this analysis. Compared with non-LGB individuals, LGB individuals had higher odds of reporting poor oral health overall in both the unadjusted (OR = 1.20 95 % CI = 1.04–1.38) and adjusted (OR= 1.21 95 % CI 1.04–1.40) analyses. After stratifying by sex and adjusting for covariates, LGB women had 38 % increased odds of having poor oral health compared with their non-LGB counterparts (OR= 1.38 95 % CI 1.14–1.67). Sexual orientation was not associated with poor oral health in males, with adjusted odds close to null comparing LBG men with their non-LGB counterparts (OR = 0.98, 95 % CI = 0.74–1.29). The findings in this study indicate more work is needed to improve oral health in the LGB community, an often underserved population, and advances health equity promotion. Findings can inform oral health prevention and reduce health disparities among LGB populations.
这项研究调查了异性恋和性取向少数的成年人之间潜在的口腔健康差异,同时也调查了性取向和口腔健康不良之间的性别差异。汇总数据(2007-2016)来自18-59岁男性和女性的国家健康和营养检查调查。采用多元逻辑回归模型检验性取向与自我报告口腔健康之间的关系。该分析包括来自20,298名参与者的数据。与非LGB个体相比,在未经调整(OR= 1.20 95 % CI = 1.04-1.38)和调整(OR= 1.21 95 % CI 1.04-1.40)分析中,LGB个体报告总体口腔健康状况不佳的几率更高。在按性别分层并调整协变量后,与非LGB女性相比,LGB女性口腔健康状况不佳的几率增加了38% % (OR= 1.38 95 % CI 1.14-1.67)。性取向与男性口腔健康状况不佳无关,LBG男性与非lgb男性的调整后比值接近零(OR = 0.98, 95 % CI = 0.74-1.29)。这项研究的结果表明,需要做更多的工作来改善LGB社区的口腔健康,这是一个经常得不到充分服务的人群,并促进健康公平。研究结果可以为LGB人群的口腔健康预防和减少健康差距提供信息。
{"title":"Oral health disparities between LGB and non-LGB individuals in the United States","authors":"R. Andrew Yockey","doi":"10.1016/j.glmedi.2025.100223","DOIUrl":"10.1016/j.glmedi.2025.100223","url":null,"abstract":"<div><div>This study examines potential oral health disparities among both heterosexual and sexual minority adults while also investigating sex-based differences in the association between sexual orientation and poor oral health. Pooled data (2007–2016) were used from the National Health and Nutrition Examination Survey for men and women aged 18–59. Multiple logistic regression models were used to examine the association between sexual orientation and self-reported oral health. Data from 20,298 participants were included in this analysis. Compared with non-LGB individuals, LGB individuals had higher odds of reporting poor oral health overall in both the unadjusted (OR = 1.20 95 % CI = 1.04–1.38) and adjusted (OR= 1.21 95 % CI 1.04–1.40) analyses. After stratifying by sex and adjusting for covariates, LGB women had 38 % increased odds of having poor oral health compared with their non-LGB counterparts (OR= 1.38 95 % CI 1.14–1.67). Sexual orientation was not associated with poor oral health in males, with adjusted odds close to null comparing LBG men with their non-LGB counterparts (OR = 0.98, 95 % CI = 0.74–1.29). The findings in this study indicate more work is needed to improve oral health in the LGB community, an often underserved population, and advances health equity promotion. Findings can inform oral health prevention and reduce health disparities among LGB populations.</div></div>","PeriodicalId":100804,"journal":{"name":"Journal of Medicine, Surgery, and Public Health","volume":"8 ","pages":"Article 100223"},"PeriodicalIF":0.0,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145939025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanistic basis of multidrug resistance: Current status, challenges, and potential solutions 多药耐药的机制基础:现状、挑战和潜在的解决方案
Pub Date : 2025-12-23 DOI: 10.1016/j.glmedi.2025.100224
Tikam Chand Dakal , Ramgopal Dhakar , Malika Ahuja , Bhana Ram Gadi , Narendra Kumar Sharma
The emergence of drug-resistant microbes is a significant global health concern, driven by the inappropriate and excessive use of antibiotics across sectors worldwide, which has led to the development of antimicrobial resistance (AMR). The rise of multidrug-resistant organisms has posed substantial challenges for healthcare systems globally, with the history of AMR tracing back to the discovery of penicillin. The improper use of antibiotics in human and animal healthcare, along with their application in agriculture, contributes to the spread of resistance genes, leading to a "Silent Pandemic" that could surpass other causes of death by 2050. AMR complicates the effective treatment of infections, affecting both human and animal populations. Bacteria can withstand the effects of antibiotics by employing several strategies, such as forming biofilms and undergoing enzymatic changes. If not addressed, the lack of effective antibiotics could jeopardize common medical procedures and potentially result in millions of deaths each year. The economic impact of AMR is expected to impose enormous financial burdens and projected losses in the trillions of dollars for healthcare systems and agriculture. Adopting a One Health strategy that considers human, animal, and environmental aspects is crucial for effectively tackling AMR. This includes enhancing surveillance systems, advocating stewardship programs, and allocating funding to research and development to discover new antibiotic alternatives. To address AMR and ensure the effectiveness of antibiotics for future generations, it is essential to prioritize raising public awareness, providing education, and fostering international collaboration.
耐药微生物的出现是一个重大的全球健康问题,其驱动因素是世界各地各部门不适当和过度使用抗生素,从而导致抗菌素耐药性的发展。耐多药生物的兴起给全球卫生保健系统带来了重大挑战,抗菌素耐药性的历史可以追溯到青霉素的发现。在人类和动物保健中不当使用抗生素,加上抗生素在农业中的应用,助长了耐药性基因的传播,导致一场“无声的大流行”,到2050年可能超过其他死亡原因。抗菌素耐药性使感染的有效治疗复杂化,影响到人类和动物种群。细菌可以通过几种策略来抵抗抗生素的作用,例如形成生物膜和经历酶的变化。如果不加以解决,有效抗生素的缺乏可能危及普通医疗程序,并可能导致每年数百万人死亡。抗菌素耐药性的经济影响预计将给医疗保健系统和农业带来巨大的财政负担和数万亿美元的预计损失。采用考虑人类、动物和环境因素的“同一个健康”战略对于有效应对抗生素耐药性至关重要。这包括加强监测系统,倡导管理项目,并为研发划拨资金,以发现新的抗生素替代品。为解决抗生素耐药性问题并确保抗生素对子孙后代的有效性,必须优先考虑提高公众认识、提供教育和促进国际合作。
{"title":"Mechanistic basis of multidrug resistance: Current status, challenges, and potential solutions","authors":"Tikam Chand Dakal ,&nbsp;Ramgopal Dhakar ,&nbsp;Malika Ahuja ,&nbsp;Bhana Ram Gadi ,&nbsp;Narendra Kumar Sharma","doi":"10.1016/j.glmedi.2025.100224","DOIUrl":"10.1016/j.glmedi.2025.100224","url":null,"abstract":"<div><div>The emergence of drug-resistant microbes is a significant global health concern, driven by the inappropriate and excessive use of antibiotics across sectors worldwide, which has led to the development of antimicrobial resistance (AMR). The rise of multidrug-resistant organisms has posed substantial challenges for healthcare systems globally, with the history of AMR tracing back to the discovery of penicillin. The improper use of antibiotics in human and animal healthcare, along with their application in agriculture, contributes to the spread of resistance genes, leading to a \"Silent Pandemic\" that could surpass other causes of death by 2050. AMR complicates the effective treatment of infections, affecting both human and animal populations. Bacteria can withstand the effects of antibiotics by employing several strategies, such as forming biofilms and undergoing enzymatic changes. If not addressed, the lack of effective antibiotics could jeopardize common medical procedures and potentially result in millions of deaths each year. The economic impact of AMR is expected to impose enormous financial burdens and projected losses in the trillions of dollars for healthcare systems and agriculture. Adopting a One Health strategy that considers human, animal, and environmental aspects is crucial for effectively tackling AMR. This includes enhancing surveillance systems, advocating stewardship programs, and allocating funding to research and development to discover new antibiotic alternatives. To address AMR and ensure the effectiveness of antibiotics for future generations, it is essential to prioritize raising public awareness, providing education, and fostering international collaboration.</div></div>","PeriodicalId":100804,"journal":{"name":"Journal of Medicine, Surgery, and Public Health","volume":"8 ","pages":"Article 100224"},"PeriodicalIF":0.0,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145938934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Social and political activism in scientific medical journals: Belief-based evidence or evidence-based beliefs? 科学医学期刊中的社会和政治激进主义:基于信念的证据还是基于证据的信念?
Pub Date : 2025-12-01 DOI: 10.1016/j.glmedi.2025.100222
Jagdish Khubchandani, Andrew Yockey, Kavita Batra
Scientific medical journals are increasingly becoming focal points in social and political discussions. The rise of mass and social media, access to technology, global health emergencies, rapidly changing policy climates, societal divisions, and economic upheavals have expanded the reach of journal publications beyond just scientific circles and into the wider public conversation. This editorial delves into the intricate role of activism within journals dedicated to medicine, surgery, and public health. We characterize activism as the act of taking explicit moral, social, or political stances that go beyond merely reporting evidence neutrally, and we investigate its possible advantages and disadvantages for scientific integrity, clinical practice, and public trust. Also, given the varying political and social landscapes globally, we discuss the implications of activism in scientific medical journals for clinicians, researchers, authors, the general public, and journal editors. In conclusion, we assert that while activism may not necessarily be incompatible with scientific publishing, it should be approached with a significant purpose, grounded in facts, and after careful consideration of its nature/ scope to prevent undermining the fundamental mission of scientific journals (i.e., to advance reliable, objective, and clinically relevant knowledge or publish science that improves public health).
科学医学期刊正日益成为社会和政治讨论的焦点。大众媒体和社交媒体的兴起、技术的普及、全球突发卫生事件、快速变化的政策气候、社会分化和经济动荡,使期刊出版物的影响范围超出了科学界,进入了更广泛的公众对话。这篇社论深入探讨了激进主义在医学、外科和公共卫生期刊中的复杂作用。我们将行动主义描述为采取明确的道德、社会或政治立场的行为,而不仅仅是中立地报道证据,我们调查了它在科学诚信、临床实践和公众信任方面可能存在的利弊。此外,考虑到全球不同的政治和社会景观,我们讨论了科学医学期刊中行动主义对临床医生、研究人员、作者、公众和期刊编辑的影响。总之,我们断言,虽然行动主义不一定与科学出版不相容,但应该带着一个重要的目的,以事实为基础,在仔细考虑其性质/范围后,以防止破坏科学期刊的基本使命(即,推进可靠、客观和临床相关的知识,或发表改善公共卫生的科学)。
{"title":"Social and political activism in scientific medical journals: Belief-based evidence or evidence-based beliefs?","authors":"Jagdish Khubchandani,&nbsp;Andrew Yockey,&nbsp;Kavita Batra","doi":"10.1016/j.glmedi.2025.100222","DOIUrl":"10.1016/j.glmedi.2025.100222","url":null,"abstract":"<div><div>Scientific medical journals are increasingly becoming focal points in social and political discussions. The rise of mass and social media, access to technology, global health emergencies, rapidly changing policy climates, societal divisions, and economic upheavals have expanded the reach of journal publications beyond just scientific circles and into the wider public conversation. This editorial delves into the intricate role of activism within journals dedicated to medicine, surgery, and public health. We characterize activism as the act of taking explicit moral, social, or political stances that go beyond merely reporting evidence neutrally, and we investigate its possible advantages and disadvantages for scientific integrity, clinical practice, and public trust. Also, given the varying political and social landscapes globally, we discuss the implications of activism in scientific medical journals for clinicians, researchers, authors, the general public, and journal editors. In conclusion, we assert that while activism may not necessarily be incompatible with scientific publishing, it should be approached with a significant purpose, grounded in facts, and after careful consideration of its nature/ scope to prevent undermining the fundamental mission of scientific journals (i.e., to advance reliable, objective, and clinically relevant knowledge or publish science that improves public health).</div></div>","PeriodicalId":100804,"journal":{"name":"Journal of Medicine, Surgery, and Public Health","volume":"7 ","pages":"Article 100222"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145750160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Variations in interest to participate in health research: Insights from the Florida Statewide Registry for Aging Studies (FSRAS). 参与健康研究的兴趣变化:来自佛罗里达州全州老龄化研究登记处(FSRAS)的见解。
Pub Date : 2025-12-01 Epub Date: 2025-08-06 DOI: 10.1016/j.glmedi.2025.100211
Jennifer E Akpo, Caitlin Murphy, Dawn Gardier, John E Ebireri, Trudy Gaillard, Lori A Bilello, Fern J Webb
<p><strong>Introduction: </strong>There is low participation in health research, particularly among racial and ethnically diverse groups. The persistent barriers contributing to low participation include mistrust, lack of information, cultural differences, and access issues. An understanding of the factors influencing willingness to participate across various types of research is important to improving participation and ensuring diverse, representative participation in health research.</p><p><strong>Methods: </strong>The study utilized data collected through the Florida Statewide Registry for Aging Studies (FSRAS), which included 481 participants aged 25 years and older. We performed descriptive statistics, bivariate analysis, and multivariate logistic regression. The primary outcome variable was interest in participating in a general health research study, as well as specific studies, including taking medication, providing a blood sample, undergoing overnight hospital stays, participating in a genetic study, accessing medical records, and using medical equipment.</p><p><strong>Results: </strong>The final analysis included 481 FSRAS participants, predominantly female (78 %), Black/African American (52 %), aged 25-64 years (78 %), and college-educated (57 %). Most resided in South Florida (53 %) and were U.S.-born (61 %). A majority of participants (82 %) reported good/excellent health. Trust in research was generally high or medium (88 %). In contrast, only 14 % reported cultural beliefs influenced willingness to participate. Participants with low trust in research were significantly less likely to express interest in general research participation (OR=0.188, 95 % CI=0.068-0.523), studies involving medical records (OR=0.366, 95 % CI=0.151-0.890), and medication use (OR=0.199, 95 % CI=0.015-0.972). Those with medium trust were less likely to express interest in studies involving blood samples (OR=0.589, 95 % CI=0.364-0.955), genetic samples (OR=0.616, 95 % CI=0.382-0.995), and medical equipment (OR=1.933, 95 % CI=1.035-3.611). Participants in fair (OR=0.359, 95 % CI=0.158-0.813) and good health (OR=0.423, 95 % CI=0.229-0.780) were less likely to participate in studies accessing medical records. Those in good health were also less likely to participate in medication studies (OR=0.298, 95 % CI=0.108-0.824). Conversely, participants in poor health were more likely to participate in genetic research (OR=10.214, 95 % CI=1.023-101.984). Regionally, participants from Central Florida were more likely to report interest in general research (OR=3.098, 95 % CI=1.725-5.565), and those from North Florida were more likely to report interest in research involving overnight hospital stays (OR=2.891, 95 % CI=1.256-6.656).</p><p><strong>Conclusion: </strong>Trust in research, along with key sociodemographic factors such as education, race/ethnicity, health status, and geographic location, significantly influenced willingness to participate in health research. These
导言:卫生研究的参与率很低,特别是在不同种族和族裔群体中。导致低参与度的持续障碍包括不信任、缺乏信息、文化差异和获取问题。了解影响参与各类研究意愿的因素,对于改善参与和确保健康研究的多样化、代表性参与非常重要。方法:该研究利用了佛罗里达全州老龄化研究登记处(FSRAS)收集的数据,其中包括481名年龄在25岁及以上的参与者。我们进行了描述性统计、双变量分析和多变量逻辑回归。主要结果变量是参与一般健康研究以及特定研究的兴趣,包括服药、提供血液样本、住院过夜、参与基因研究、获取医疗记录和使用医疗设备。结果:最终分析包括481名FSRAS参与者,主要是女性(78%),黑人/非裔美国人(52%),年龄在25-64岁(78%),受过大学教育(57%)。大多数居住在南佛罗里达(53%),在美国出生(61%)。大多数参与者(82%)报告健康状况良好/非常好。对研究的信任度一般为高或中等(88%)。相比之下,只有14%的人认为文化信仰影响了他们的参与意愿。对研究信任度低的参与者对一般研究参与(OR=0.188, 95% CI=0.068-0.523)、涉及医疗记录的研究(OR=0.366, 95% CI=0.151-0.890)和药物使用(OR=0.199, 95% CI=0.015-0.972)表达兴趣的可能性显著降低。那些具有中等信任度的人不太可能对涉及血液样本(OR=0.589, 95% CI=0.364-0.955)、基因样本(OR=0.616, 95% CI=0.382-0.995)和医疗设备(OR=1.933, 95% CI=1.035-3.611)的研究表现出兴趣。健康状况良好(OR=0.359, 95% CI=0.158-0.813)和健康状况良好(OR=0.423, 95% CI=0.229-0.780)的受试者较少参与查阅医疗记录的研究。那些健康状况良好的人参加药物研究的可能性也较小(OR=0.298, 95% CI=0.108-0.824)。相反,健康状况不佳的参与者更有可能参与基因研究(OR=10.214, 95% CI=1.023-101.984)。从地区来看,来自佛罗里达州中部的参与者更有可能报告对一般研究的兴趣(OR=3.098, 95% CI=1.725-5.565),而来自北佛罗里达州的参与者更有可能报告对涉及过夜住院的研究的兴趣(OR=2.891, 95% CI=1.256-6.656)。结论:对研究的信任,以及关键的社会人口因素,如教育、种族/民族、健康状况和地理位置,显著影响参与健康研究的意愿。这些研究结果强调需要制定包容性的、建立信任的战略,以加强和促进对卫生研究的多样化参与。
{"title":"Variations in interest to participate in health research: Insights from the Florida Statewide Registry for Aging Studies (FSRAS).","authors":"Jennifer E Akpo, Caitlin Murphy, Dawn Gardier, John E Ebireri, Trudy Gaillard, Lori A Bilello, Fern J Webb","doi":"10.1016/j.glmedi.2025.100211","DOIUrl":"10.1016/j.glmedi.2025.100211","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;There is low participation in health research, particularly among racial and ethnically diverse groups. The persistent barriers contributing to low participation include mistrust, lack of information, cultural differences, and access issues. An understanding of the factors influencing willingness to participate across various types of research is important to improving participation and ensuring diverse, representative participation in health research.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;The study utilized data collected through the Florida Statewide Registry for Aging Studies (FSRAS), which included 481 participants aged 25 years and older. We performed descriptive statistics, bivariate analysis, and multivariate logistic regression. The primary outcome variable was interest in participating in a general health research study, as well as specific studies, including taking medication, providing a blood sample, undergoing overnight hospital stays, participating in a genetic study, accessing medical records, and using medical equipment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The final analysis included 481 FSRAS participants, predominantly female (78 %), Black/African American (52 %), aged 25-64 years (78 %), and college-educated (57 %). Most resided in South Florida (53 %) and were U.S.-born (61 %). A majority of participants (82 %) reported good/excellent health. Trust in research was generally high or medium (88 %). In contrast, only 14 % reported cultural beliefs influenced willingness to participate. Participants with low trust in research were significantly less likely to express interest in general research participation (OR=0.188, 95 % CI=0.068-0.523), studies involving medical records (OR=0.366, 95 % CI=0.151-0.890), and medication use (OR=0.199, 95 % CI=0.015-0.972). Those with medium trust were less likely to express interest in studies involving blood samples (OR=0.589, 95 % CI=0.364-0.955), genetic samples (OR=0.616, 95 % CI=0.382-0.995), and medical equipment (OR=1.933, 95 % CI=1.035-3.611). Participants in fair (OR=0.359, 95 % CI=0.158-0.813) and good health (OR=0.423, 95 % CI=0.229-0.780) were less likely to participate in studies accessing medical records. Those in good health were also less likely to participate in medication studies (OR=0.298, 95 % CI=0.108-0.824). Conversely, participants in poor health were more likely to participate in genetic research (OR=10.214, 95 % CI=1.023-101.984). Regionally, participants from Central Florida were more likely to report interest in general research (OR=3.098, 95 % CI=1.725-5.565), and those from North Florida were more likely to report interest in research involving overnight hospital stays (OR=2.891, 95 % CI=1.256-6.656).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Trust in research, along with key sociodemographic factors such as education, race/ethnicity, health status, and geographic location, significantly influenced willingness to participate in health research. These","PeriodicalId":100804,"journal":{"name":"Journal of Medicine, Surgery, and Public Health","volume":"7 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12774470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145919561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Platelet-rich plasma administration to reduce surgical interventions and improve functional outcomes in patients who have failed physical therapy 富血小板血浆给药减少手术干预并改善物理治疗失败患者的功能结局
Pub Date : 2025-11-29 DOI: 10.1016/j.glmedi.2025.100220
Steven M. Hadley Jr. , Rachel Bergman , John J. Peabody , Nathan Repasky , Sarah J. Westvold , Ryan Filler , Milap Patel , Anish R. Kadakia
The benefit of platelet-rich plasma (PRP) injections for foot and ankle conditions remains controversial. No studies have evaluated validated Patient Reported Outcomes Measurement Information System (PROMIS) measures of physical function (PF) and pain interference (PI) following PRP. Because PROMIS is validated in foot and ankle and exhibits improved reliability and generalizability compared to other commonly used patient-reported metrics, this study aimed to investigate functional outcomes measured by PROMIS following PRP for foot and ankle pathologies. This investigation was a retrospective study of all 81 patients who underwent PRP therapy for any foot and ankle pathology at a single institution (2018–2023). All patients had PRP for any foot and ankle pathology after failing 6–8 weeks of physical therapy and prior to any surgical intervention. 81 patients were contacted via phone and email up to five attempts to complete surveys containing PROMIS, as well as additional questions regarding ability to increase activity compared to pre-injection baseline and whether PRP injection was worth out-of-pocket costs. PROMIS was developed for a US population mean score of 50. Higher PF indicates better physical function, whereas higher PI designates more pain. Primary outcome was PROMIS PF and PI. Secondary outcomes were ability to increase activity compared to pre-injection baseline, self-reported pain resolution, whether surgery was pursued, and whether patients believed PRP was worth out-of-pocket costs. Mean follow-up was 28 months. Across all pathologies, mean PROMIS PF and PI were 49.1 ± 7.3 and 51.6 ± 8.5, respectively. Patients with plantar fasciitis (N = 4) had highest average PF (58.2 ± 6.0) and lowest average PI (42.9 ± 5.4). Insertional Achilles tendinosis (N = 6) and non-insertional Achilles tendinosis (N = 7) exhibited average PFs of 50.8 ± 5.3 and 50.2 ± 4.4, respectively, and PIs of 46.4 ± 7.2 and 49.7 ± 5.7, respectively. Average PF and PI by pathology were, respectively, peroneal tendinosis 45.8 ± 3.8 and 56.0 ± 8.3, posterior tibialis tendinosis 49.0 ± 4 and 50.8 ± 10.4, and ankle arthritis 48.0 ± 9.5 and 53.5 ± 7.2. 75 % (N = 35/47) of patients increased activity following PRP. 23 % (N = 11/47) had complete resolution of pain after PRP. 83 % (N = 39/47) did not pursue surgery following PRP. 77 % (N = 36/47) agreed that PRP was worth the out-of-pocket cost. Most patients who received PRP for various foot and ankle pathologies scored population mean PROMIS scores, increased activity, avoided surgery, and believed PRP was worth out-of-pocket costs. While our results may suggest a potential role for PRP to be offered as a reasonable nonoperative treatment option for foot and ankle pathology, further studies with larger samples are needed to evaluate PROMIS after PRP.
富血小板血浆(PRP)注射治疗足部和踝关节疾病的益处仍然存在争议。没有研究评估PRP后患者报告结果测量信息系统(PROMIS)测量的身体功能(PF)和疼痛干扰(PI)。由于PROMIS在足部和踝关节中得到了验证,与其他常用的患者报告的指标相比,它表现出更高的可靠性和通用性,因此本研究旨在研究PRP后PROMIS测量足部和踝关节病变的功能结果。本研究是一项回顾性研究,对在同一家机构(2018-2023年)接受PRP治疗的所有81名足部和踝关节病理患者进行了研究。所有患者在物理治疗失败6-8周后和任何手术干预前都有任何足部和踝关节病理PRP。通过电话和电子邮件联系81名患者,多达5次尝试完成包含PROMIS的调查,以及关于与注射前基线相比增加活动能力的额外问题,以及PRP注射是否值得自付费用。PROMIS是针对美国人口平均得分为50分而开发的。较高的PF表示身体功能较好,而较高的PI表示疼痛较多。主要终点为PROMIS PF和PI。次要结果是与注射前基线相比,活动能力增加,自我报告的疼痛缓解,是否进行手术,以及患者是否认为PRP值得自付费用。平均随访28个月。在所有病理中,PROMIS PF和PI的平均值分别为49.1 ± 7.3和51.6 ± 8.5。足底筋膜炎患者(N = 4)平均PF最高(58.2 ± 6.0),平均PI最低(42.9 ± 5.4)。插入阿基里斯tendinosis (N = 6)和non-insertional阿基里斯tendinosis (N = 7)表现出50.8的平均PFs ±  5.3和50.2±4.4 ,分别和π 46.4±7.2和49.7  ±5.7 ,分别。分别平均病理学PF和π的腓骨的tendinosis 45.8±3.8和56.0  ± 8.3,49.0后胫骨tendinosis ±  4和50.8±10.4 ,和踝关节炎 48.0±9.5和53.5  ±7.2 。75% % (N = 35/47)的患者在PRP后活动增加。23 % (N = 11/47)患者PRP后疼痛完全缓解。83 % (N = 39/47)患者在PRP后未进行手术。77 % (N = 36/47)同意PRP值得自付费用。大多数因各种足部和踝关节病变接受PRP的患者得分为人口平均PROMIS得分,活动增加,避免手术,并认为PRP值得自付费用。虽然我们的研究结果可能表明PRP作为一种合理的非手术治疗足部和踝关节病理的潜在作用,但需要进一步的大样本研究来评估PRP后的PROMIS。
{"title":"Platelet-rich plasma administration to reduce surgical interventions and improve functional outcomes in patients who have failed physical therapy","authors":"Steven M. Hadley Jr. ,&nbsp;Rachel Bergman ,&nbsp;John J. Peabody ,&nbsp;Nathan Repasky ,&nbsp;Sarah J. Westvold ,&nbsp;Ryan Filler ,&nbsp;Milap Patel ,&nbsp;Anish R. Kadakia","doi":"10.1016/j.glmedi.2025.100220","DOIUrl":"10.1016/j.glmedi.2025.100220","url":null,"abstract":"<div><div>The benefit of platelet-rich plasma (PRP) injections for foot and ankle conditions remains controversial. No studies have evaluated validated Patient Reported Outcomes Measurement Information System (PROMIS) measures of physical function (PF) and pain interference (PI) following PRP. Because PROMIS is validated in foot and ankle and exhibits improved reliability and generalizability compared to other commonly used patient-reported metrics, this study aimed to investigate functional outcomes measured by PROMIS following PRP for foot and ankle pathologies. This investigation was a retrospective study of all 81 patients who underwent PRP therapy for any foot and ankle pathology at a single institution (2018–2023). All patients had PRP for any foot and ankle pathology after failing 6–8 weeks of physical therapy and prior to any surgical intervention. 81 patients were contacted via phone and email up to five attempts to complete surveys containing PROMIS, as well as additional questions regarding ability to increase activity compared to pre-injection baseline and whether PRP injection was worth out-of-pocket costs. PROMIS was developed for a US population mean score of 50. Higher PF indicates better physical function, whereas higher PI designates more pain. Primary outcome was PROMIS PF and PI. Secondary outcomes were ability to increase activity compared to pre-injection baseline, self-reported pain resolution, whether surgery was pursued, and whether patients believed PRP was worth out-of-pocket costs. Mean follow-up was 28 months. Across all pathologies, mean PROMIS PF and PI were 49.1 ± 7.3 and 51.6 ± 8.5, respectively. Patients with plantar fasciitis (N = 4) had highest average PF (58.2 ± 6.0) and lowest average PI (42.9 ± 5.4). Insertional Achilles tendinosis (N = 6) and non-insertional Achilles tendinosis (N = 7) exhibited average PFs of 50.8 ± 5.3 and 50.2 ± 4.4, respectively, and PIs of 46.4 ± 7.2 and 49.7 ± 5.7, respectively. Average PF and PI by pathology were, respectively, peroneal tendinosis 45.8 ± 3.8 and 56.0 ± 8.3, posterior tibialis tendinosis 49.0 ± 4 and 50.8 ± 10.4, and ankle arthritis 48.0 ± 9.5 and 53.5 ± 7.2. 75 % (N = 35/47) of patients increased activity following PRP. 23 % (N = 11/47) had complete resolution of pain after PRP. 83 % (N = 39/47) did not pursue surgery following PRP. 77 % (N = 36/47) agreed that PRP was worth the out-of-pocket cost. Most patients who received PRP for various foot and ankle pathologies scored population mean PROMIS scores, increased activity, avoided surgery, and believed PRP was worth out-of-pocket costs. While our results may suggest a potential role for PRP to be offered as a reasonable nonoperative treatment option for foot and ankle pathology, further studies with larger samples are needed to evaluate PROMIS after PRP.</div></div>","PeriodicalId":100804,"journal":{"name":"Journal of Medicine, Surgery, and Public Health","volume":"8 ","pages":"Article 100220"},"PeriodicalIF":0.0,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145652048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Coxsackievirus A16 caused hand-foot-mouth disease in a young male: A case report 柯萨奇病毒A16致年轻男性手足口病1例报告
Pub Date : 2025-11-07 DOI: 10.1016/j.glmedi.2025.100219
Majd Oweidat , Marwan Alkum , Diaa Qaisiya , Majd Nemer Zawahrah , Bisan Hamza Ragabi , Safwat Zidat
Hand–foot–and–mouth disease (HFMD) is typically a pediatric illness, yet adults may be affected and overlooked. We report an immunocompetent 24-year-old man with a 3-day prodrome of fever, myalgia, sore throat, and headache, followed by intensely pruritic palmoplantar lesions with sparse oral disease. Examination revealed numerous 2–4 mm painless erythematous macules and papules on the palms, fewer on the soles and peri-oral skin, and a single tender soft-palate ulcer. Differential diagnoses included herpes simplex, varicella zoster, erythema multiforme, secondary syphilis, drug eruption, and scabies. Stool polymerase chain reaction confirmed Coxsackievirus A16. Supportive care consisted of antihistamines, non-steroidal anti-inflammatory drugs, topical calamine–zinc oxide, and oral hyaluronic acid gel. Pruritus resolved by day 2; mucocutaneous lesions regressed without complications and were nearly resolved with palmar desquamation by day 9. This case highlights an adult, pruritus-predominant, minimally vesicular phenotype with scant oral involvement and no childcare exposure. Clinicians should consider HFMD in adults with palmoplantar eruptions and emphasize symptomatic management and hygiene counseling to limit transmission.
手足口病(手足口病)通常是一种儿科疾病,但成年人可能受到影响并被忽视。我们报告一位免疫功能正常的24岁男性,其前驱症状为发热、肌痛、喉咙痛和头痛,随后出现强烈的掌足底瘙痒性病变并伴有稀疏的口腔疾病。检查发现手掌有大量2-4 毫米的无痛性红斑和丘疹,鞋底和口周皮肤较少,单发软腭溃疡。鉴别诊断包括单纯疱疹、水痘带状疱疹、多形性红斑、继发性梅毒、药疹和疥疮。粪便聚合酶链反应确诊柯萨奇病毒A16。支持治疗包括抗组胺药、非甾体抗炎药、外用氧化锌和口服透明质酸凝胶。瘙痒在第2天消退;皮肤粘膜病变消退,无并发症,到第9天手掌脱屑几乎消失。本病例为成人,瘙痒为主,极少有水泡表型,很少累及口腔,无托儿暴露。临床医生应考虑有掌足底疹的成人手足口病,并强调症状管理和卫生咨询,以限制传播。
{"title":"Coxsackievirus A16 caused hand-foot-mouth disease in a young male: A case report","authors":"Majd Oweidat ,&nbsp;Marwan Alkum ,&nbsp;Diaa Qaisiya ,&nbsp;Majd Nemer Zawahrah ,&nbsp;Bisan Hamza Ragabi ,&nbsp;Safwat Zidat","doi":"10.1016/j.glmedi.2025.100219","DOIUrl":"10.1016/j.glmedi.2025.100219","url":null,"abstract":"<div><div>Hand–foot–and–mouth disease (HFMD) is typically a pediatric illness, yet adults may be affected and overlooked. We report an immunocompetent 24-year-old man with a 3-day prodrome of fever, myalgia, sore throat, and headache, followed by intensely pruritic palmoplantar lesions with sparse oral disease. Examination revealed numerous 2–4 mm painless erythematous macules and papules on the palms, fewer on the soles and peri-oral skin, and a single tender soft-palate ulcer. Differential diagnoses included herpes simplex, varicella zoster, erythema multiforme, secondary syphilis, drug eruption, and scabies. Stool polymerase chain reaction confirmed Coxsackievirus A16. Supportive care consisted of antihistamines, non-steroidal anti-inflammatory drugs, topical calamine–zinc oxide, and oral hyaluronic acid gel. Pruritus resolved by day 2; mucocutaneous lesions regressed without complications and were nearly resolved with palmar desquamation by day 9. This case highlights an adult, pruritus-predominant, minimally vesicular phenotype with scant oral involvement and no childcare exposure. Clinicians should consider HFMD in adults with palmoplantar eruptions and emphasize symptomatic management and hygiene counseling to limit transmission.</div></div>","PeriodicalId":100804,"journal":{"name":"Journal of Medicine, Surgery, and Public Health","volume":"7 ","pages":"Article 100219"},"PeriodicalIF":0.0,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145465708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of potential confounding factors for the evaluation of clinical outcomes in alpha-1-antitrypsin deficiency-associated liver disease 鉴定评估α -1抗胰蛋白酶缺乏相关性肝病临床结果的潜在混杂因素
Pub Date : 2025-10-24 DOI: 10.1016/j.glmedi.2025.100217
Heiner Wedemeyer , Frank Tacke , Christoph Berg , Christian M. Lange , Pavel Strnad , Andreas Hahn , Thomas Welsh , Daniela Skalt , Stephanie Sussmann , Robert Kudernatsch

Background

Alpha-1-Antitrypsin deficiency (AATD) is a common but only rarely recognized genetic condition predisposing to e.g., liver disease. Systematic identification and classification of confounding factors is needed for the evaluation of clinical outcomes in adults with AATD-associated liver disease.

Methods

A stepwise systematic review was performed to identify relevant guidelines and recommendations, systematic reviews and meta-analyses, and observational studies and randomized clinical trials. Five experts with large long-term experience recruited via purposeful sampling were consulted for validation via open requests and a joint workshop. A list was consented and categorized by clinical relevance and type of influence. Relations were visualized in a directed acyclic graph.

Results

Cirrhosis and fibrosis stage, genotype, sex, diabetes, obesity were categorized as very important; age, alcohol and metabolic syndrome were consented to be relevant but less important factors affecting distinct stages of liver disease. Adjusting for diabetes, obesity, alcohol consumption, and metabolic syndrome as confounders; stratifying or testing for interactions with sex and age as potential effect modifiers; and including cirrhosis, fibrosis stage, and genotype as prognostic factors to improve outcome prediction in AATD studies is suggested. Presented results require cautious interpretation due to varying evidence levels of included literature.

Conclusions

The results obtained through a transparent and reproducible systematic approach aid future studies to improve design and analytical strategies for AATD-associated liver diseases. They enable a precise and accurate estimation of treatment effects with reduced risk of bias. In practice, this enhances the evidence base for innovative therapies for adults with AATD-associated liver disease.
背景:α -1抗胰蛋白酶缺乏症(AATD)是一种常见但很少被认识到的遗传病,易导致肝病等疾病。评估成人aatd相关肝病的临床结果需要系统地识别和分类混杂因素。方法采用逐步系统评价方法,确定相关指南和建议、系统评价和荟萃分析、观察性研究和随机临床试验。通过有目的的抽样招募了五名具有丰富长期经验的专家,并通过公开请求和联合讲习班进行了咨询。同意了一份清单,并按临床相关性和影响类型进行分类。关系在有向无环图中可视化。结果肝硬化和纤维化分期、基因型、性别、糖尿病、肥胖是重要因素;年龄、酒精和代谢综合征被认为是影响不同阶段肝病的相关但不太重要的因素。调整糖尿病、肥胖、饮酒和代谢综合征等混杂因素;分层或测试与性别和年龄的相互作用作为潜在的影响调节因素;并建议将肝硬化、纤维化分期和基因型作为预后因素,以改善AATD研究的预后预测。由于纳入文献的证据水平不同,提出的结果需要谨慎解释。结论通过透明和可重复的系统方法获得的结果有助于未来研究改进aatd相关肝脏疾病的设计和分析策略。它们能够精确和准确地估计治疗效果,降低偏倚风险。在实践中,这增强了创新治疗成人aatd相关肝病的证据基础。
{"title":"Identification of potential confounding factors for the evaluation of clinical outcomes in alpha-1-antitrypsin deficiency-associated liver disease","authors":"Heiner Wedemeyer ,&nbsp;Frank Tacke ,&nbsp;Christoph Berg ,&nbsp;Christian M. Lange ,&nbsp;Pavel Strnad ,&nbsp;Andreas Hahn ,&nbsp;Thomas Welsh ,&nbsp;Daniela Skalt ,&nbsp;Stephanie Sussmann ,&nbsp;Robert Kudernatsch","doi":"10.1016/j.glmedi.2025.100217","DOIUrl":"10.1016/j.glmedi.2025.100217","url":null,"abstract":"<div><h3>Background</h3><div>Alpha-1-Antitrypsin deficiency (AATD) is a common but only rarely recognized genetic condition predisposing to e.g., liver disease. Systematic identification and classification of confounding factors is needed for the evaluation of clinical outcomes in adults with AATD-associated liver disease.</div></div><div><h3>Methods</h3><div>A stepwise systematic review was performed to identify relevant guidelines and recommendations, systematic reviews and meta-analyses, and observational studies and randomized clinical trials. Five experts with large long-term experience recruited via purposeful sampling were consulted for validation via open requests and a joint workshop. A list was consented and categorized by clinical relevance and type of influence. Relations were visualized in a directed acyclic graph.</div></div><div><h3>Results</h3><div>Cirrhosis and fibrosis stage, genotype, sex, diabetes, obesity were categorized as very important; age, alcohol and metabolic syndrome were consented to be relevant but less important factors affecting distinct stages of liver disease. Adjusting for diabetes, obesity, alcohol consumption, and metabolic syndrome as confounders; stratifying or testing for interactions with sex and age as potential effect modifiers; and including cirrhosis, fibrosis stage, and genotype as prognostic factors to improve outcome prediction in AATD studies is suggested. Presented results require cautious interpretation due to varying evidence levels of included literature.</div></div><div><h3>Conclusions</h3><div>The results obtained through a transparent and reproducible systematic approach aid future studies to improve design and analytical strategies for AATD-associated liver diseases. They enable a precise and accurate estimation of treatment effects with reduced risk of bias. In practice, this enhances the evidence base for innovative therapies for adults with AATD-associated liver disease.</div></div>","PeriodicalId":100804,"journal":{"name":"Journal of Medicine, Surgery, and Public Health","volume":"7 ","pages":"Article 100217"},"PeriodicalIF":0.0,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145527856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Towards personalized diabetes management: Identifying stability for efficient care using primary care data 迈向个性化糖尿病管理:利用初级保健数据确定有效护理的稳定性
Pub Date : 2025-10-18 DOI: 10.1016/j.glmedi.2025.100218
Sukainah A. Alfaraj , Rimke C. Vos , Marco Spruit , Rolf H.H. Groenwold , Dennis Mook-Kanamori
Type 2 diabetes mellitus (T2DM) is largely managed in primary care, where Dutch guidelines recommend quarterly follow-ups. Many T2DM individuals maintain long-term glycaemic control and may not need such frequent visits. We conducted a retrospective cohort study using routinely collected data from the Extramural Leiden University Medical Center Academic Network (ELAN) linked to Statistics Netherlands to identify those with stable diabetes and predict ongoing control. We examined 47,801 adults with T2DM aged 40–79 years and formed two cohorts: the metformin cohort, which included individuals newly starting metformin (n = 21,307), and the random-time cohort, which included individuals using any glucose-lowering medication at a random point in their disease course (n = 22,245). Stability was defined as maintaining glycated hemoglobin (HbA1c) ≤ 53 mmol/mol (7 %) for one year without additional diabetes medication or dose adjustment. Logistic regression models were used to examine whether first-year stability predicted glycaemic control in the second year. Additional models adjusted for demographic and clinical factors, including age, sex, body mass index, blood pressure, High-Density Lipoprotein (HDL) cholesterol, eGFR, smoking, migration status, and household income. Models performance was evaluated with the area under the receiver operating characteristic curve (AUC), and continuous variables were standardized to allow comparison across measures. All analyses were performed using R (version 4.2.1). In the metformin cohort, 23 % of participants achieved glycaemic stability during the first year of follow-up. Among the individuals who achieved stability in the first year, 82 % maintained this stable glycaemic control throughout the second year. First-year stability was strongly associated with continued control during the second year (odds ratio [OR] 89, 95 % confidence interval [CI] 81–99) with excellent discrimination (AUC 0.89). Adding other predictors increased the AUC only slightly to 0.91. Findings were similar in the random time cohort: 46 % were stable in the first year, and 80 % of these remained stable in the second year. First-year stability alone was a strong predictor (OR 25, 95 % CI 23–26) with an AUC of 0.84, rising modestly to 0.85 with additional predictors. One year of stable glycaemic control is a powerful indicator of future stability and could support a more tailored approach to diabetes follow-up. Reducing visit frequency for well-controlled individuals may help optimize primary care resources, reduce unnecessary workload, and lessen the burden of frequent clinic visits. These findings could inform updates to follow-up recommendations and support the use of remote monitoring and self-management to individualize diabetes care.
2型糖尿病(T2DM)主要在初级保健中进行管理,荷兰指南建议每季度随访一次。许多2型糖尿病患者维持长期血糖控制,可能不需要如此频繁的就诊。我们进行了一项回顾性队列研究,使用与荷兰统计局相关的校外莱顿大学医学中心学术网络(ELAN)常规收集的数据来识别稳定型糖尿病患者并预测持续控制。我们检查了47,801名年龄在40-79岁的T2DM患者,并形成了两个队列:二甲双胍队列,其中包括新开始使用二甲双胍的个体(n = 21,307),以及随机时间队列,其中包括在疾病过程中随机点使用任何降糖药物的个体(n = 22245)。稳定性定义为维持糖化血红蛋白(HbA1c)≤ 53 mmol/mol(7 %)一年,无需额外的糖尿病药物或剂量调整。使用逻辑回归模型来检验第一年的稳定性是否预测第二年的血糖控制。其他模型根据人口统计学和临床因素进行调整,包括年龄、性别、体重指数、血压、高密度脂蛋白(HDL)胆固醇、eGFR、吸烟、移民状况和家庭收入。用受试者工作特征曲线(AUC)下的面积来评估模型的性能,并对连续变量进行标准化,以便进行跨测量的比较。所有分析均使用R(版本4.2.1)进行。在二甲双胍队列中,23% %的参与者在随访的第一年达到了血糖稳定。在第一年达到稳定的个体中,82% %在第二年保持稳定的血糖控制。第一年的稳定性与第二年的持续控制密切相关(优势比[OR] 89,95 %置信区间[CI] 81-99),鉴别性极好(AUC 0.89)。加上其他预测因子,AUC仅略微增加到0.91。随机时间队列的研究结果相似:46% %在第一年稳定,80% %在第二年保持稳定。第一年的稳定性是一个强有力的预测因子(OR 25, 95 % CI 23-26), AUC为0.84,加上其他预测因子,AUC小幅上升至0.85。一年稳定的血糖控制是未来稳定的有力指标,可以支持更有针对性的糖尿病随访方法。对于控制良好的个体,减少就诊频率可能有助于优化初级保健资源,减少不必要的工作量,并减轻频繁就诊的负担。这些发现可以为后续建议的更新提供信息,并支持使用远程监测和自我管理来个性化糖尿病护理。
{"title":"Towards personalized diabetes management: Identifying stability for efficient care using primary care data","authors":"Sukainah A. Alfaraj ,&nbsp;Rimke C. Vos ,&nbsp;Marco Spruit ,&nbsp;Rolf H.H. Groenwold ,&nbsp;Dennis Mook-Kanamori","doi":"10.1016/j.glmedi.2025.100218","DOIUrl":"10.1016/j.glmedi.2025.100218","url":null,"abstract":"<div><div>Type 2 diabetes mellitus (T2DM) is largely managed in primary care, where Dutch guidelines recommend quarterly follow-ups. Many T2DM individuals maintain long-term glycaemic control and may not need such frequent visits. We conducted a retrospective cohort study using routinely collected data from the Extramural Leiden University Medical Center Academic Network (ELAN) linked to Statistics Netherlands to identify those with stable diabetes and predict ongoing control. We examined 47,801 adults with T2DM aged 40–79 years and formed two cohorts: the metformin cohort, which included individuals newly starting metformin (n = 21,307), and the random-time cohort, which included individuals using any glucose-lowering medication at a random point in their disease course (n = 22,245). Stability was defined as maintaining glycated hemoglobin (HbA1c) ≤ 53 mmol/mol (7 %) for one year without additional diabetes medication or dose adjustment. Logistic regression models were used to examine whether first-year stability predicted glycaemic control in the second year. Additional models adjusted for demographic and clinical factors, including age, sex, body mass index, blood pressure, High-Density Lipoprotein (HDL) cholesterol, eGFR, smoking, migration status, and household income. Models performance was evaluated with the area under the receiver operating characteristic curve (AUC), and continuous variables were standardized to allow comparison across measures. All analyses were performed using R (version 4.2.1). In the metformin cohort, 23 % of participants achieved glycaemic stability during the first year of follow-up. Among the individuals who achieved stability in the first year, 82 % maintained this stable glycaemic control throughout the second year. First-year stability was strongly associated with continued control during the second year (odds ratio [OR] 89, 95 % confidence interval [CI] 81–99) with excellent discrimination (AUC 0.89). Adding other predictors increased the AUC only slightly to 0.91. Findings were similar in the random time cohort: 46 % were stable in the first year, and 80 % of these remained stable in the second year. First-year stability alone was a strong predictor (OR 25, 95 % CI 23–26) with an AUC of 0.84, rising modestly to 0.85 with additional predictors. One year of stable glycaemic control is a powerful indicator of future stability and could support a more tailored approach to diabetes follow-up. Reducing visit frequency for well-controlled individuals may help optimize primary care resources, reduce unnecessary workload, and lessen the burden of frequent clinic visits. These findings could inform updates to follow-up recommendations and support the use of remote monitoring and self-management to individualize diabetes care.</div></div>","PeriodicalId":100804,"journal":{"name":"Journal of Medicine, Surgery, and Public Health","volume":"7 ","pages":"Article 100218"},"PeriodicalIF":0.0,"publicationDate":"2025-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145362177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Medicine, Surgery, and Public Health
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1